Nishant Krishna Sekaran1, Anna Lisa Crowley1, Fernanda Rodrigues de Souza2, Elmiro Santos Resende2, Sunil V Rao3. 1. Durham Veterans Affairs Health System, Duke University Medical Center, Durham, NC, 27710, USA. 2. Department of Cardiology and Clinical Hospital, Federal University of Uberlandia, Uberlandia, Brazil. 3. Durham Veterans Affairs Health System, Duke University Medical Center, Durham, NC, 27710, USA. sunil.rao@duke.edu.
Abstract
PURPOSE OF REVIEW: Ischemic and non-ischemic injury to the heart causes deleterious changes in ventricular size, shape, and function. This adverse remodeling is mediated by neurohormonal and hemodynamic alterations and is reflected in non-invasive measures of left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). These measures are closely linked to cardiovascular outcomes and have become key surrogate endpoints for evaluating the therapeutic efficacy of contemporary treatments for heart failure with reduced ejection fraction (HFrEF). In this review, we critically evaluate recent published data (2015-2016) from randomized clinical trials (RCTs) and observational studies of HFrEF therapies to assess the role of ventricular remodeling on outcomes. RECENT FINDINGS: These data highlight the benefits of certain guideline-directed medical therapies (GDMT) such as cardiac resynchronization therapy, surgical revascularization, and mechanical circulatory support on remodeling, while revealing the limitations of other therapies-routine mitral valve repair for patients with moderate ischemic mitral regurgitation and adjuncts to percutaneous coronary intervention in patients with ST elevation myocardial infarction (cyclosporine A and bioabsorbable cardiac matrix). The new angiotensin receptor blocker/neprilysn inhibitor, sacubitril/valsartan, demonstrates convincing improvements in clinical outcomes with a study of remodeling parameters to follow; the new cardiac myosin activator, omecamtiv mecarbil, demonstrates improvement in remodeling parameters without a clear early clinical benefit. The concepts and contemporary trials reviewed in this paper reinforce the value of non-invasive measures of ventricular remodeling (LVEF, LVESV, and LVEDV) as important metrics across a range of cardiovascular therapies. Global non-invasive measures of cardiovascular remodeling have roughly paralleled or preceded hard clinical outcomes. Additionally, the capacity for reverse remodeling in HFrEF with GDMT motivates continued research in the fields of implementation science, diagnostic imaging, and gene-based therapeutics.
PURPOSE OF REVIEW: Ischemic and non-ischemic injury to the heart causes deleterious changes in ventricular size, shape, and function. This adverse remodeling is mediated by neurohormonal and hemodynamic alterations and is reflected in non-invasive measures of left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). These measures are closely linked to cardiovascular outcomes and have become key surrogate endpoints for evaluating the therapeutic efficacy of contemporary treatments for heart failure with reduced ejection fraction (HFrEF). In this review, we critically evaluate recent published data (2015-2016) from randomized clinical trials (RCTs) and observational studies of HFrEF therapies to assess the role of ventricular remodeling on outcomes. RECENT FINDINGS: These data highlight the benefits of certain guideline-directed medical therapies (GDMT) such as cardiac resynchronization therapy, surgical revascularization, and mechanical circulatory support on remodeling, while revealing the limitations of other therapies-routine mitral valve repair for patients with moderate ischemic mitral regurgitation and adjuncts to percutaneous coronary intervention in patients with ST elevation myocardial infarction (cyclosporine A and bioabsorbable cardiac matrix). The new angiotensin receptor blocker/neprilysn inhibitor, sacubitril/valsartan, demonstrates convincing improvements in clinical outcomes with a study of remodeling parameters to follow; the new cardiac myosin activator, omecamtiv mecarbil, demonstrates improvement in remodeling parameters without a clear early clinical benefit. The concepts and contemporary trials reviewed in this paper reinforce the value of non-invasive measures of ventricular remodeling (LVEF, LVESV, and LVEDV) as important metrics across a range of cardiovascular therapies. Global non-invasive measures of cardiovascular remodeling have roughly paralleled or preceded hard clinical outcomes. Additionally, the capacity for reverse remodeling in HFrEF with GDMT motivates continued research in the fields of implementation science, diagnostic imaging, and gene-based therapeutics.
Authors: Jens-Uwe Voigt; Gianni Pedrizzetti; Peter Lysyansky; Tom H Marwick; Hélène Houle; Rolf Baumann; Stefano Pedri; Yasuhiro Ito; Yasuhiko Abe; Stephen Metz; Joo Hyun Song; Jamie Hamilton; Partho P Sengupta; Theodore J Kolias; Jan d'Hooge; Gerard P Aurigemma; James D Thomas; Luigi Paolo Badano Journal: J Am Soc Echocardiogr Date: 2015-02 Impact factor: 5.251
Authors: John R Teerlink; G Michael Felker; John J V McMurray; Piotr Ponikowski; Marco Metra; Gerasimos S Filippatos; Justin A Ezekowitz; Kenneth Dickstein; John G F Cleland; Jae B Kim; Lei Lei; Beat Knusel; Andrew A Wolff; Fady I Malik; Scott M Wasserman Journal: J Am Coll Cardiol Date: 2016-03-29 Impact factor: 24.094
Authors: Michel G Khouri; Ronald M Peshock; Colby R Ayers; James A de Lemos; Mark H Drazner Journal: Circ Cardiovasc Imaging Date: 2010-01-08 Impact factor: 7.792
Authors: Mariya Mollova; Kevin Bersell; Stuart Walsh; Jainy Savla; Lala Tanmoy Das; Shin-Young Park; Leslie E Silberstein; Cristobal G Dos Remedios; Dionne Graham; Steven Colan; Bernhard Kühn Journal: Proc Natl Acad Sci U S A Date: 2013-01-09 Impact factor: 11.205
Authors: Eric J Velazquez; Kerry L Lee; Robert H Jones; Hussein R Al-Khalidi; James A Hill; Julio A Panza; Robert E Michler; Robert O Bonow; Torsten Doenst; Mark C Petrie; Jae K Oh; Lilin She; Vanessa L Moore; Patrice Desvigne-Nickens; George Sopko; Jean L Rouleau Journal: N Engl J Med Date: 2016-04-03 Impact factor: 91.245
Authors: Cecilia Castro-Diehl; Rebecca J Song; Douglas B Sawyer; Kai C Wollert; Gary F Mitchell; Susan Cheng; Ramachandran S Vasan; Vanessa Xanthakis Journal: Int J Cardiol Date: 2021-01-07 Impact factor: 4.164